Sugi Predict

Sugi Predict / Compounds / SCHEMBL23115

SCHEMBL23115

SCHEMBL23115

COc1ccc(OBOc2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.67
▸ CA12 O43570 1/20 0.67
▸ CA1 P00915 1/20 0.67
▸ CA7 P43166 1/20 0.67
▸ CA9 Q16790 1/20 0.67
▸ CA14 Q9ULX7 1/20 0.67
▸ ACHE P22303 1/20 0.48
▸ TUBB4A P04350 1/20 0.47
▸ TUBB P07437 1/20 0.47
▸ TUBA3C P0DPH7 1/20 0.47
▸ TUBA1B P68363 1/20 0.47
▸ TUBA4A P68366 1/20 0.47
▸ TUBB4B P68371 1/20 0.47
▸ TUBB3 Q13509 1/20 0.47
▸ TUBB2A Q13885 1/20 0.47
▸ TUBB8 Q3ZCM7 1/20 0.47
▸ TUBA3E Q6PEY2 1/20 0.47
▸ TUBA1A Q71U36 1/20 0.47
▸ TUBA1C Q9BQE3 1/20 0.47
▸ TUBB6 Q9BUF5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963842 0.84 CA12 (0.71) CA2CA12CA1CA7CA9
SCHEMBL290040 0.84 CA12 (0.71) CA2CA12CA1CA7CA9
SCHEMBL23052 0.83 CA12 (0.45) CA2CA12CA1CA7CA9
SCHEMBL10224469 0.83 CA2 (0.61) CA2CA12CA1CA7CA9
SCHEMBL23744 0.83 CA12 (0.45) CA2CA12CA1CA7CA9
SCHEMBL430118 0.82 FDPS (0.46) CA2CA12CA1CA7CA9
SCHEMBL177471 0.81 CA12 (0.43) CA2CA12CA1CA7CA9
SCHEMBL12003966 0.81 CA12 (0.43) CA2CA12CA1CA7CA9
SCHEMBL17181780 0.81 ALDH1A1 (0.68) CA2CA12CA1CA7CA9
SCHEMBL15521889 0.81 CA12 (0.43) CA2CA12CA1CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109305895-A The method for preparing spirofluorene derivative unimolecule resin using one still process 深圳前海广宇天骥科技有限公司 2019-02-05 — — CN claimed
CN-103804196-B Star-shaped adamantane derivative molecular glass and preparation method and application thereof 中国科学院理化技术研究所 2016-08-31 — — CN claimed
CN-104557552-A Star-shaped tetraphenylethylene derivative molecular glass, positive photoresist coating and application thereof CHINESE ACAD TECH INST PHYSICS 2015-04-29 — — CN claimed
US-20250340537-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING PENDRIN ARBORMED CO LTD (KR) 2025-11-06 — — US disclosed
EP-4642775-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING PENDRIN Arbormed Co., Ltd. (KR) 2025-11-05 — — EP disclosed
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-08-05 — — US disclosed
US-20250236616-A1 IMMUNOMODULATING AZALIDES ZOETIS SERVICES LLC 2025-07-24 — — US disclosed
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-06-19 — — US disclosed
US-20250059207-A1 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS 858 THERAPEUTICS, INC. 2025-02-20 — — US disclosed
EP-3885348-B1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR KOREA RES INST CHEMICAL TECH (KR) 2025-02-12 — — EP disclosed
US-20250017910-A1 2-Thioxothiazolidine-4-One Derivatives And Their Uses PROSETTA BIOSCIENCES, INC. 2025-01-16 — — US disclosed
WO-2001023365-A1 QUINAZOLINONES MERCK PATENT GMBH (DE) 2001-04-05 — — WO disclosed
WO-2001023364-A1 QUINAZOLINONES MERCK PATENT GMBH (DE) 2001-04-05 — — WO disclosed
WO-2000077001-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES DU PONT PHARMACEUTICALS COMPANY (US) 2000-12-21 — — WO disclosed
EP-1021429-A1 ARYL FURAN DERIVATIVES AS PDE IV INHIBITORS MERCK FROSST CANADA INC. (CA) 2000-07-26 — — EP disclosed
US-6020339-A Aryl furan derivatives as PDE IV inhibitors MERCK & CO., INC. (US) 2000-02-01 — — US disclosed
WO-1999018095-A1 ARYL FURAN DERIVATIVES AS PDE IV INHIBITORS MERCK FROSST CANADA & CO. (CA) 1999-04-15 — — WO disclosed
EP-0811001-A1 BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-12-10 — — EP disclosed
US-5599811-A PHENYL OR DIOXYPHENYL SUBSTITUENTS; DRUGS WARNER-LAMBERT COMPANY (US) 1997-02-04 — — US disclosed
WO-1996026195-A1 BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1996-08-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340537-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING PENDRIN SLC26A4, PTH1R, PKD1 CA2 392/4885CA12 1210/4885CA1 1649/4885
US-20250017910-A1 2-Thioxothiazolidine-4-One Derivatives And Their Uses COMT, SLC6A3, TPMT CA2 4503/4885CA12 4763/4885CA1 4757/4885
US-20250059207-A1 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, METTL16, TPMT CA2 4824/4885CA12 4758/4885CA1 4871/4885
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor IRAK4, IRAK1, IRAK2 CA2 2097/4885CA12 3705/4885CA1 2727/4885
US-20250236616-A1 IMMUNOMODULATING AZALIDES IL2, MALT1, FCGRT CA2 3281/4885CA12 2077/4885CA1 1803/4885
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE TDP1, TYMP, TARDBP CA2 4856/4885CA12 4860/4885CA1 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.